Clinical Innovation Catalyst Program Addresses Pediatric Adverse Drug Events

The Institute for Pediatric Innovation (IPI) is pleased to announce that the 2017-2018 Clinical Innovation Catalyst Program is focusing on Adverse Drug Events (ADEs). 

American Society for Health-System Pharmacists defines an ADE as "any unexpected, unintended, undesired, or excessive response to a drug." This hospital acquired condition can result in prolonging the patient's stay in a healthcare facility, permanent harm, disability and even death. Healthcare providers may be penalized by payors for ADEs, receive negative publicity, and be exposed to litigation. 

ADEs can be especially life threatening for newborns and young children since this population is usually less able to physiologically tolerate a medical error due to their still-developing renal, immune and liver functions. Pediatric ADEs are also problematic because children may not be able to effectively communicate any adverse effects a medication is causing.

For more information, check out our press release on PRWeb.